In view of the fact that BNP is a biological marker of left ventricular systolic function, we propose a hypothesis whether BNP can be used to predict the existence of subclinical functional and morphological damage of the left ventricle in cancer patients with PD-1/PD-L1 inhibitors. The gene discussed is PDCD1; the disease is cancer.